Zimmer Biomet Holdings (ZBH) Valuation After Evercore ISI Upgrade And Shifting Analyst Sentiment
Zimmer Biomet Holdings (ZBH) has come back into focus after Evercore ISI Group shifted its rating to Outperform, a change that follows earlier downgrades such as Raymond James moving to Market Perform.
See our latest analysis for Zimmer Biomet Holdings.
Zimmer Biomet’s recent rating upgrade comes after a mixed share price return pattern, with a 3.1% 7 day gain contrasting with a 4.8% 90 day share price decline and a weaker 1 year total shareholder return of 7.8%. This suggests momentum has been soft rather than strongly trending either way as the stock trades around $92.67.
If Zimmer Biomet’s move has you looking across the sector, this could be a good moment to sift through other US healthcare names using healthcare stocks.
With the shares around $92.67, trading at a discount to both some analyst targets and one intrinsic value estimate, the central question is whether Zimmer Biomet is currently mispriced or whether the market already reflects its future growth potential.
Most Popular Narrative: 9.2% Undervalued
Zimmer Biomet’s most followed narrative points to a fair value close to US$102 per share, compared with the recent close near US$92.67, framing the current discount as a valuation gap tied to execution on growth plans and capital allocation.
The analysts have a consensus price target of $110.917 for Zimmer Biomet Holdings based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $138.0, and the most bearish reporting a price target of just $96.0.
Curious what sits behind that fair value and the tight analyst spread? The story leans heavily on steadier revenue gains, firmer margins, and a different earnings power by the late 2020s. The specific growth, profitability and valuation assumptions are already mapped out. The question is whether you agree with how much is baked in.
Result: Fair Value of $102.04 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the whole story could shift if pricing pressure in core orthopedics persists, or if acquisitions and new robotics platforms take longer than expected to deliver.
Find out about the key risks to this Zimmer Biomet Holdings narrative.
Build Your Own Zimmer Biomet Holdings Narrative
If you see the numbers differently or prefer to test your own assumptions, you can build a tailored Zimmer Biomet view in minutes, starting with Do it your way.
A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
Looking for more investment ideas?
If Zimmer Biomet has sparked your interest, do not stop there. Broader opportunities could suit your goals even better, so give yourself more options to compare.
- Spot potential mispricings by scanning these 884 undervalued stocks based on cash flows that share similar valuation gaps or cash flow support to what you are weighing here.
- Tap into trends reshaping technology by checking out these 26 AI penny stocks that lean on artificial intelligence for products, services, or long term growth themes.
- Boost your income focus by reviewing these 12 dividend stocks with yields > 3% that combine meaningful yields with the potential for more stable cash returns over time.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com